{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:08:59Z","timestamp":1793686139696,"version":"4.5.1"},"reference-count":110,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide guidance to rheumatology providers on the use of COVID\u201019 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A task force was assembled that included 9 rheumatologists\/immunologists, 2 infectious diseases specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID\u201019 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9\u2010point numerical scoring system, using a modified Delphi process and the RAND\/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite a paucity of direct evidence, statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID\u201019 vaccines, including supplemental\/booster dosing, in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These guidance statements are intended to provide direction to rheumatology health care providers on how to best use COVID\u201019 vaccines and to facilitate implementation of vaccination strategies for RMD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.42372","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T03:05:34Z","timestamp":1667876734000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["American College of Rheumatology Guidance for\n                    <scp>COVID<\/scp>\n                    \u201019 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5"],"prefix":"10.1002","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R.","family":"Curtis","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-2976","authenticated-orcid":false,"given":"Sindhu R.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital Mount Sinai Hospital, and University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1226-5976","authenticated-orcid":false,"given":"Donald D.","family":"Anthony","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland VA Medical Center MetroHealth Medical Center, and Case Western Reserve University  Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben J.","family":"Arasaratnam","sequence":"additional","affiliation":[{"name":"VA North Texas Health Care System and University of Texas Southwestern Medical Center  Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-8351","authenticated-orcid":false,"given":"Anne R.","family":"Bass","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery and Weill Cornell Medicine  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Cleveland Clinic  Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Gravallese","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Harpaz","sequence":"additional","affiliation":[{"name":"Harpaz Herman Consultants  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kroger","sequence":"additional","affiliation":[{"name":"CDC  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-3565","authenticated-orcid":false,"given":"Rebecca E.","family":"Sadun","sequence":"additional","affiliation":[{"name":"Duke University  Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7695-2022","authenticated-orcid":false,"given":"Amy S.","family":"Turner","sequence":"additional","affiliation":[{"name":"American College of Rheumatology  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor Anderson","family":"Williams","sequence":"additional","affiliation":[{"name":"The Permanente Medical Group  Union City California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0897-2272","authenticated-orcid":false,"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center and VA Nebraska\u2013Western Iowa Health Care System  Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40448"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41596"},{"key":"e_1_2_8_4_1","unstructured":"US Food and Drug Administration.Vaccines and Related Biological Products Advisory Committee meeting: FDA briefing document Pfizer\u2010BioNTech COVID\u201019 vaccine. December 2020. URL:https:\/\/www.fda.gov\/media\/144245\/download."},{"key":"e_1_2_8_5_1","unstructured":"US Food and Drug Administration.Vaccines and Related Biological Products Advisory Committee meeting: FDA briefing document Moderna COVID\u201019 vaccine. December 2020. URL:https:\/\/www.fda.gov\/media\/144434\/download."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41752"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001035"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.04.014"},{"key":"e_1_2_8_14_1","unstructured":"American College of Rheumatology.American College of Rheumatology Guidance Subcommittee and Endorsement of Guidance Documents 2020. URL:https:\/\/www.rheumatology.org\/Portals\/0\/Files\/ACR-Guidance-Subcommittee-Processes-Framework.pdf."},{"key":"e_1_2_8_15_1","volume-title":"The RAND\/UCLA appropriateness method user's manual","author":"Fitch K","year":"2001"},{"key":"e_1_2_8_16_1","unstructured":"American College of Rheumatology. COVID\u201019 guidance. URL:https:\/\/www.rheumatology.org\/Practice\u2010Quality\/Clinical\u2010Support\/COVID\u201019\u2010Guidance."},{"key":"e_1_2_8_17_1","unstructured":"ModernaTX sponsor. A study to evaluate the safety reactogenicity and effectiveness of mRNA\u20101273 vaccine in adolescents 12 to <18\u2009years old to prevent COVID\u201019 (TeenCove).ClinicalTrials.govidentifier: NCT04649151."},{"key":"e_1_2_8_18_1","unstructured":"BioNTech SE and Pfizer sponsors.Study to describe the safety tolerability immunogenicity and efficacy of RNA vaccine candidates against COVID\u201019 in healthy individuals.ClinicalTrials.govidentifier: NCT04368728."},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention.Pfizer\u2010BioNTech COVID\u201019 vaccine (5 through 11\u2009years of age). February2022.https:\/\/www.cdc.gov\/vaccines\/covid\u201019\/info\u2010by\u2010product\/pfizer\/pfizer\u2010bioNTech\u2010children\u2010adolescents.html.","DOI":"10.1007\/s40278-022-15739-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116298"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit816"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-158"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.12.003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39670"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa897"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41619"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11252"},{"issue":"1","key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/annrheumdis-2021-eular.1466","article-title":"COVID\u201019 hospitalizations, ICU admission, and death among patients with immune mediated inflammatory diseases (IMID) \u2010 a population based study [abstract]","volume":"80","author":"Eder L","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41567"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219498"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11221"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031364"},{"key":"e_1_2_8_38_1","unstructured":"Centers for Disease Control and Prevention.Vaccine recommendations and guidelines of the ACIP: COVID\u201019 vaccine recommendations. March 2021. URL:https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/vacc-specific\/covid-19.html."},{"key":"e_1_2_8_39_1","unstructured":"Centers for Disease Control and Prevention.Vaccines and immunizations: Interim considerations\u2014preparing for the potential management of anaphylaxis after COVID\u201019. vaccination. March 2021. URL:https:\/\/www.cdc.gov\/vaccines\/covid\u201019\/clinical\u2010considerations\/managing\u2010anaphylaxis.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid\u201019%2Finfo\u2010by\u2010product%2Fpfizer%2Fanaphylaxis\u2010management.html."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160685"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2\u2009weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park JK","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202281"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04857-y"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215187"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211128"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218440"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30396-9"},{"key":"e_1_2_8_48_1","unstructured":"Centers for Disease Control and Prevention.COVID\u201019 vaccines for people who are moderately or severelyimmunocompromised. September2022. URL:https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis670"},{"key":"e_1_2_8_50_1","unstructured":"Centers for Disease Control and Prevention.Vaccines and immunizations: interim clinical considerations for use of COVID\u201019 vaccines currently authorized in the United States. July 16 2021. URL:https:\/\/www.cdc.gov\/vaccines\/covid\u201019\/info\u2010by\u2010product\/clinical\u2010considerations.html."},{"key":"e_1_2_8_51_1","unstructured":"Centers for Disease Control and Prevention.Stay up to date with COVID\u201019 Vaccines including boosters. September 2022. URL:https:\/\/www.cdc.gov\/coronavirus\/2019\u2010ncov\/vaccines\/booster\u2010shot.html."},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.05.044"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7489"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220289"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2111462"},{"key":"e_1_2_8_56_1","unstructured":"Centers for Disease Control and Prevention.Science brief: COVID\u201019 vaccines and vaccination2021. September 2021. URL:https:\/\/www.cdc.gov\/coronavirus\/2019\u2010ncov\/science\/science\u2010briefs\/fully\u2010vaccinated\u2010people.html."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj4176"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","unstructured":"WuK ChoiA KochM LingZhiM HillA NunnaN et al.Preliminary analysis of safety and immunogenicity of a SARS\u2013CoV\u20102 variant vaccine booster [preprint]. medRxiv2021.","DOI":"10.1101\/2021.05.05.21256716"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7034e2"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26672-3"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107058"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01413-7"},{"key":"e_1_2_8_63_1","unstructured":"AtmarRL LykeKE DemingME JacksonLA BrancheAR El SahlyHM et al.Heterologous SARS\u2010CoV\u20102 booster vaccinations \u2010 preliminary report [preprint]. medRxiv2021."},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01891-2"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01420-3"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2110716"},{"key":"e_1_2_8_67_1","unstructured":"RoseR NeumannF GrobeN LorentzT FickenscherHK A. Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS\u2010CoV\u20102 which is comparable to that according to a homologous mRNA vaccination scheme [preprint]. medRxiv2021."},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103761"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01464-w"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01449-9"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00221-6"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221539"},{"key":"e_1_2_8_74_1","unstructured":"Centers for Disease Control and Prevention.Effectiveness of BNT162b2 (Pfizer\u2010BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12\u201318 years \u2014 United States July. December 2021. URL:https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7102e1.htm."},{"key":"e_1_2_8_75_1","article-title":"Outcomes after SARS\u2010CoV\u20102 vaccination among children with a history of multisystem inflammatory syndrome","volume":"5","author":"Wisniewski M, Chun A, Volpi S, Muscal E, Sexson Tejtel SK, Munoz F, Vogel TP","year":"2022","journal-title":"JAMA Netw Open"},{"key":"e_1_2_8_76_1","unstructured":"Centers for Disease Control and Prevention.Interim clinical considerations for use of COVID\u201019 vaccines currently approved or authorized in the United States. September 2022. URL:https:\/\/www.cdc.gov\/vaccines\/covid\u201019\/clinical\u2010considerations\/interim\u2010considerations\u2010us.html#covid19\u2010vaccination\u2010misc\u2010mis."},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20465"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-T"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201393"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204427"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202658"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201950"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.843743"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0662-x"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030455"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001041"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.081"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001018"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010380"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-494096"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.06.017"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13495"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22246"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.25033"},{"key":"e_1_2_8_96_1","first-page":"S945","article-title":"Immunosuppression attenuates antibody and neutralization titers in patients with chronic inflammatory disease following SARS\u2010CoV\u20102 vaccination [abstract]","volume":"73","author":"Paley MA","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110721"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-207"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221571"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114255"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.7326\/M21-1757"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220626"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3910058"},{"key":"e_1_2_8_105_1","article-title":"VROOM study investigators. Effect of a 2\u2010week interruption in methotrexate treatment versus continued treatment on COVID\u201019 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial","volume":"10","author":"Abhishek A, Boyton RJ, Peckham N, McKnight \u00c1, Coates LC, Bluett J, Barber V, Cureton L, et al.","year":"2022","journal-title":"Lancet Respir Med"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001847"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221252"},{"key":"e_1_2_8_108_1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2\u2009weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park JK","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00251-4"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00351-9"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1183077"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42372","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.42372","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:34:26Z","timestamp":1759923266000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/art.42372"],"URL":"https:\/\/doi.org\/10.1002\/art.42372","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"2022-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}